Euroapi: another 5% on the counter!











Photo credit © Sanofi Corporate


(Boursier.com) — The days go by and are alike for Euroapi. The company specializing in the manufacture of chemical molecules for drugs aligns a third session of strong progress this morning, on a gain of 5.5% to 14.55 euros. The company split from Sanofi made its debut on the Paris market on Friday at a price of 12 euros. The title continues to benefit from the support of analysts who are beginning to follow the file. This morning, Deutsche Bank and Oddo BHF initiated the coverage ofEuroapi with a positive review.

DB, ‘Buy’ with a target of 20 euros, explains that given its leading position in structural growth markets and its initiatives to become more efficient following the split from Sanofi, the company is well equipped to achieve its objective of strong and profitable growth in the future.

Oddo BHF (‘outperform and target of 17.8 euros) asserts that independent of Sanofi, Euroapi has the opportunity to catch up financially with its peers by applying a clear and well-defined strategy. The solidity of its activity, the sector dynamics and the forecast growth of EBITDA give the company an attractive profile which could soon benefit from a leverage effect via acquisitions (zero debt today).


©2022 Boursier.com






Source link -87